日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Real-world safety and tolerability of rapid infusion obinutuzumab in chronic lymphocytic leukemia, small lymphocytic lymphoma and non-Hodgkin lymphoma: a provincial review

快速输注奥妥珠单抗治疗慢性淋巴细胞白血病、小淋巴细胞淋巴瘤和非霍奇金淋巴瘤的真实世界安全性和耐受性:一项省级综述

Senthil, Harshal; Streilein, Scott; Whiteside, Theresa; Minuk, Leonard; Landego, Ivan; Kotb, Rami; Menard, Chantalle; Kansara, Roopesh; Moltzan, Catherine J; Johnston, James B; Skrabek, Pamela; Yang, Lin; Geirnaert, Marc; Banerji, Versha

Venetoclax in Combination with Obinutuzumab in Previously Untreated Fit Patients with Chronic Lymphocytic Leukemia: A Canadian Cost-Utility Analysis

维奈托克联合奥妥珠单抗治疗既往未接受治疗的慢性淋巴细胞白血病健康患者:一项加拿大成本效益分析

van de Wetering, Gijs; Owen, Carolyn; Banerji, Versha; Gosselin, Ariane; Kamdar, Shivani; Roc, Nancy Paul; Bakker, Lytske; Ratnaparkhi, Gargi; Barakat, Stephane; Vicente, Colin; Manzoor, Beenish S

Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN

在ELEVATE-TN研究的6年随访结果中,阿卡替尼联合奥妥珠单抗治疗与化疗免疫疗法相比,可改善初治慢性淋巴细胞白血病患者的生存期。

Sharman, Jeff P; Egyed, Miklos; Jurczak, Wojciech; Skarbnik, Alan; Patel, Krish; Flinn, Ian W; Kamdar, Manali; Munir, Talha; Walewska, Renata; Hughes, Marie; Fogliatto, Laura Maria; Herishanu, Yair; Banerji, Versha; Follows, George; Walker, Patricia; Ghia, Paolo; Janssens, Ann; Byrd, John C; Ferrant, Emmanuelle; Ferrajoli, Alessandra; Wierda, William G; Wachira, Catherine Wangui; Suterwala, Batul T; Miranda, Paulo; Munugalavadla, Veerendra; Wun, Chuan-Chuan; Woyach, Jennifer A

Disease stage-specific role of the mitochondrial pyruvate carrier suppresses differentiation in temozolomide and radiation-treated glioblastoma

线粒体丙酮酸载体在疾病阶段特异性作用下抑制替莫唑胺和放射治疗的胶质母细胞瘤的分化

Martell, Emma; Kuzmychova, Helgi; Senthil, Harshal; Chawla, Ujala; Kaul, Esha; Grewal, Akaljot; Banerji, Versha; Anderson, Christopher M; Venugopal, Chitra; Miller, Donald; Werbowetski-Ogilvie, Tamra E; Singh, Sheila K; Sharif, Tanveer

Correction: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia

更正:ELEVATE-TN 研究 4 年随访结果显示,在初治慢性淋巴细胞白血病患者中,阿卡替尼联合或不联合奥妥珠单抗与奥妥珠单抗联合苯丁酸氮芥的疗效和安全性。

Sharman, Jeff P; Egyed, Miklos; Jurczak, Wojciech; Skarbnik, Alan; Pagel, John M; Flinn, Ian W; Kamdar, Manali; Munir, Talha; Walewska, Renata; Corbett, Gillian; Fogliatto, Laura Maria; Herishanu, Yair; Banerji, Versha; Coutre, Steven; Follows, George; Walker, Patricia; Karlsson, Karin; Ghia, Paolo; Janssens, Ann; Cymbalista, Florence; Woyach, Jennifer A; Ferrant, Emmanuelle; Wierda, William G; Munugalavadla, Veerendra; Yu, Ting; Wang, Min Hui; Byrd, John C

ATM inhibition decreases ERK activation and is synergistic with ibrutinib in primary chronic lymphocytic leukemia cells

ATM抑制剂可降低ERK活化,并与伊布替尼在原发性慢性淋巴细胞白血病细胞中具有协同作用。

Kost, Sara E F; Saleh, Ali; Brown, Jennifer; Yuan, Shek H; Kuzio, Bozena; Yang, Lin; Banerji, Versha; Gibson, Spencer B; Johnston, James B; Katyal, Sachin

Contemporary Fixed-Duration Treatment Options in the First-Line Setting of Chronic Lymphocytic Leukemia: Perspectives from a Publicly Funded Healthcare System

慢性淋巴细胞白血病一线治疗中当代固定疗程方案:来自公共医疗保健系统的视角

Lemieux, Christopher; Phua, Chai W; Robinson, K Sue; Owen, Carolyn; Banerji, Versha

A Scoping Review Mapping Trans* and Gender Diverse People's Representation in Cancer Research

癌症研究中跨性别者和性别多元人群代表性的范围界定综述

Stirling, Morgan; Bourque, Michaela A; Hunter, Mikayla; Queenan, John; Ludwig, Claire; Ristock, Janice; Harrison, Lyndsay; Ross-White, Amanda; Nickel, Nathan C; Schultz, Annette; Banerji, Versha; Gahagan, Jacqueline; Mahar, Alyson

Hairy cell leukemia variant and WHO classification correspondence Re: 5(th) edition WHO classification haematolymphoid tumors: lymphoid neoplasms

毛细胞白血病变异型与WHO分类的对应关系:第五版WHO血液淋巴瘤分类:淋巴瘤

Grever, Michael; Andritsos, Leslie; Anghelina, Mirela; Arons, Evgeny; Banerji, Versha; Barrientos, Jacqueline; Bhat, Seema A; Blachly, James; Broccoli, Alessandro; Call, Timothy; Dearden, Claire; Dietrich, Sascha; Else, Monica; Epperla, Narendranath; Fagarasanu, Andrei; Falini, Brunangelo; Forconi, Francesco; Gozzetti, Alessandro; Hampel, Paul; Hermel, David J; Iyengar, Sunil; Johnston, James B; Juliusson, Gunnar; Kreitman, Robert J; Lauria, Francesco; Lozanski, Gerard; Oakes, Christopher C; Parikh, Sameer A; Park, Jae; Quest, Graeme; Rai, Kanti; Ravandi, Farhad; Robak, Tadeusz; Rogers, Kerry A; Saven, Alan; Seymour, John F; Tadmor, Tamar; Tallman, Martin S; Tam, Constantine S; Tiacci, Enrico; Troussard, Xavier; Wörmann, Bernhard; Zent, Clive S; Zenz, Thorsten; Zinzani, Pier Luigi

DNA-PK hyperactivation occurs in deletion 11q chronic lymphocytic leukemia and is both a biomarker and therapeutic target for drug-resistant disease

DNA-PK过度激活发生于11q缺失型慢性淋巴细胞白血病中,既是耐药性疾病的生物标志物,也是治疗靶点。

Kost, Sara E F; Saleh, Ali; Yuan, Shek H; Kuzio, Bozena; Gibson, Spencer B; Yang, Lin; Banerji, Versha; Johnston, James B; Katyal, Sachin